Collaboration and Licensing Agreements - Narrative (Details) $ in Thousands, $ in Millions, ¥ in Billions	1 Months Ended				3 Months Ended		6 Months Ended			68 Months Ended
	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 CAD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jul. 31, 2023 USD ($)	Jun. 30, 2023 JPY (¥)	Apr. 30, 2023 USD ($)	Oct. 31, 2022 USD ($)	Apr. 30, 2022 USD ($) payment_tranche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					$ 22,333	$ 2,526	$ 33,702		$ 2,994
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					764	10	776		14
Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					3,260	952	3,262		966
2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues										$ 20,000
2017 KKC Agreement | Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					3,300	952	3,300		966
KKC | 2017 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees			$ 30,000
Potential development milestones			$ 55,000
Potential commercialization milestones					58,800		58,800			58,800		¥ 8.5
Fee receivable for reduction in royalty rate															$ 40,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche															2
KKC | 2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments														$ 35,000
Fosun Pharma | Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones					3,000		3,000			3,000
Upfront payment received		$ 12,000
Potential development and commercialization milestones							$ 113,000
Threshold percentage of net sales for tiered royalties							20.00%	20.00%
Fosun Pharma | Fosun Agreement | Subsequent event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments											$ 2,000
Knight | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones					700		$ 700			700
Upfront payment received	$ 2,300
Potential development and commercialization milestones							16,700	$ 22.2
METiS Therapeutics Inc | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					800		800
Proceeds from milestone payments													$ 243,000
Upfront payment													$ 800
AstraZeneca | AZ Termination Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue				10.00%
Percentage of non-royalty revenue				20.00%
Maximum potential payment per agreement				$ 75,000
Aggregate cost of revenue recognized					18,300		18,300			18,300
Aggregate amount paid					16,400		16,400			$ 16,400
Cost of revenue					$ 1,900	$ 200	$ 3,000		$ 300